Ardent Health Partners (ARDT) Financials

$14.61 -0.19 (-1.28%)

Closing price 05/23/2025 03:59 PM Eastern

Extended Trading

$14.62 +0.01 (+0.03%)

As of 05/23/2025 05:19 PM Eastern

Annual Income Statements for Ardent Health Partners

This table shows Ardent Health Partners' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Income / (Loss) Attributable to Common Shareholders	210	54	31
Consolidated Net Income / (Loss)	300	129	265
Net Income / (Loss) Continuing Operations	300	129	108
Total Pre-Tax Income	363	152	311
Total Operating Income	337	150	154
Total Gross Profit	3,431	3,025	1,539
Total Revenue	5,966	5,409	5,130
Operating Revenue	5,966	5,409	5,130
Total Cost of Revenue	2,535	2,384	3,591
Operating Cost of Revenue	2,535	2,384	3,591
Total Operating Expenses	3,095	2,875	1,385
Selling, General & Admin Expense	2,626	2,425	1,201
Depreciation Expense	146	141	138
Other Operating Expenses / (Income)	322	309	47
Total Other Income / (Expense), net	26	1.61	0.00
Other Income / (Expense), net	26	1.61	-
Income Tax Expense	63	23	46
Net Income / (Loss) Attributable to Noncontrolling Interest	89	75	76
Basic Earnings per Share	$1.59	$0.43	$1.50
Weighted Average Basic Shares Outstanding	132.44M	126.12M	126.12M
Diluted Earnings per Share	$1.58	$0.43	$1.50
Weighted Average Diluted Shares Outstanding	132.74M	126.12M	126.12M
Weighted Average Basic & Diluted Shares Outstanding	142.75M	-	-

This table shows Ardent Health Partners' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q3 2024	Q2 2024	Q3 2023	Q2 2023
Period end date	3/31/2025	9/30/2024	6/30/2024	9/30/2023	6/30/2023
Net Income / (Loss) Attributable to Common Shareholders	41	26	43	21	33
Consolidated Net Income / (Loss)	59	46	67	39	56
Net Income / (Loss) Continuing Operations	59	46	67	39	56
Total Pre-Tax Income	74	57	82	46	68
Total Operating Income	53	54	84	46	67
Total Gross Profit	840	815	847	782	770
Total Revenue	1,497	1,450	1,471	1,378	1,369
Operating Revenue	1,497	1,450	1,471	1,378	1,369
Total Cost of Revenue	658	635	624	596	598
Operating Cost of Revenue	658	635	624	596	598
Total Operating Expenses	787	760	763	736	703
Selling, General & Admin Expense	670	644	647	621	596
Depreciation Expense	36	37	36	35	35
Other Operating Expenses / (Income)	80	80	80	80	72
Total Other Income / (Expense), net	21	2.81	-1.64	0.00	0.52
Other Income / (Expense), net	21	2.81	0.26	0.00	0.52
Income Tax Expense	15	11	15	7.26	12
Net Income / (Loss) Attributable to Noncontrolling Interest	18	20	24	18	23
Basic Earnings per Share	$0.30	$0.19	$0.34	$0.17	$0.26
Weighted Average Basic Shares Outstanding	140.06M	137.11M	126.12M	126.12M	126.12M
Diluted Earnings per Share	$0.29	$0.19	$0.34	$0.17	$0.26
Weighted Average Diluted Shares Outstanding	140.70M	137.54M	126.12M	126.12M	126.12M
Weighted Average Basic & Diluted Shares Outstanding	143.04M	142.73M	142.76M	-	-

This table details how cash moves in and out of Ardent Health Partners' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Change in Cash & Equivalents	119	-19	-262
Net Cash From Operating Activities	315	222	-38
Net Cash From Continuing Operating Activities	315	222	-38
Net Income / (Loss) Continuing Operations	300	129	265
Consolidated Net Income / (Loss)	300	129	265
Depreciation Expense	146	141	138
Amortization Expense	5.47	4.99	5.70
Non-Cash Adjustments To Reconcile Net Income	26	-0.75	-323
Changes in Operating Assets and Liabilities, net	-162	-52	-125
Net Cash From Investing Activities	-220	-138	47
Net Cash From Continuing Investing Activities	-220	-138	47
Purchase of Property, Plant & Equipment	-188	-137	-151
Acquisitions	-36	0.00	0.00
Divestitures	4.30	0.00	206
Other Investing Activities, net	-1.71	-0.58	-8.69
Net Cash From Financing Activities	25	-102	-270
Net Cash From Continuing Financing Activities	25	-102	-270
Repayment of Debt	-106	-146	-28
Repurchase of Common Equity	-9.53	-26	-1.95
Payment of Dividends	-73	-64	-244
Issuance of Debt	3.60	132	0.88
Issuance of Common Equity	209	0.00	0.00
Other Financing Activities, net	0.35	1.87	2.50
Cash Interest Paid	75	82	91
Cash Income Taxes Paid	42	19	56

This table details how cash moves in and out of Ardent Health Partners' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q4 2023	Q3 2023
Period end date	3/31/2025	12/31/2024	9/30/2024	12/31/2023	9/30/2023
Net Change in Cash & Equivalents	-62	-6.36	229	-7.10	40
Net Cash From Operating Activities	-25	120	90	67	89
Net Cash From Continuing Operating Activities	-25	120	90	67	89
Net Income / (Loss) Continuing Operations	59	141	46	11	39
Consolidated Net Income / (Loss)	59	141	46	11	39
Depreciation Expense	36	38	37	36	35
Amortization Expense	1.24	1.23	1.38	0.72	1.42
Non-Cash Adjustments To Reconcile Net Income	8.03	13	8.42	-5.09	0.39
Changes in Operating Assets and Liabilities, net	-129	-73	-2.86	25	13
Net Cash From Investing Activities	-23	-105	-45	-57	-25
Net Cash From Continuing Investing Activities	-23	-105	-45	-57	-25
Purchase of Property, Plant & Equipment	-23	-81	-43	-57	-25
Acquisitions	0.00	-27	-0.24	-	-
Other Investing Activities, net	-0.21	-0.97	-0.80	0.74	0.24
Net Cash From Financing Activities	-14	-20	183	-18	-24
Net Cash From Continuing Financing Activities	-14	-20	183	-18	-24
Repayment of Debt	-2.45	3.21	-1.50	-128	-4.06
Payment of Dividends	-19	-20	-21	-13	-19
Issuance of Debt	0.00	-	1.80	130	-
Other Financing Activities, net	7.86	-3.07	1.74	-6.99	-0.98

This table presents Ardent Health Partners' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023
Period end date	12/31/2024	12/31/2023
Total Assets	4,956	4,732
Total Current Assets	1,833	1,618
Cash & Equivalents	557	438
Accounts Receivable	743	775
Inventories, net	115	105
Prepaid Expenses	114	77
Other Current Assets	304	222
Plant, Property, & Equipment, net	862	811
Total Noncurrent Assets	2,261	2,302
Goodwill	852	845
Intangible Assets	77	77
Noncurrent Deferred & Refundable Income Taxes	12	32
Other Noncurrent Operating Assets	1,320	1,348
Total Liabilities & Shareholders' Equity	4,956	4,732
Total Liabilities	3,434	3,649
Total Current Liabilities	945	994
Short-Term Debt	9.23	19
Accounts Payable	401	475
Accrued Expenses	535	501
Total Noncurrent Liabilities	2,488	2,655
Long-Term Debt	1,086	1,168
Other Noncurrent Operating Liabilities	1,403	1,487
Commitments & Contingencies	0.00	0.00
Redeemable Noncontrolling Interest	1.16	7.30
Total Equity & Noncontrolling Interests	1,521	1,075
Total Preferred & Common Equity	1,131	671
Preferred Stock	0.00	0.00
Total Common Equity	1,131	671
Common Stock	756	497
Retained Earnings	366	155
Accumulated Other Comprehensive Income / (Loss)	9.74	19
Noncontrolling Interest	390	404

This table presents Ardent Health Partners' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q3 2024	Q2 2024
Period end date	3/31/2025	9/30/2024	6/30/2024
Total Assets	4,911	4,800	4,609
Total Current Assets	1,761	1,691	1,501
Cash & Equivalents	495	563	335
Accounts Receivable	777	706	721
Inventories, net	120	108	105
Prepaid Expenses	130	120	136
Other Current Assets	239	194	205
Plant, Property, & Equipment, net	857	815	807
Total Noncurrent Assets	2,293	2,294	2,300
Goodwill	877	852	852
Intangible Assets	77	77	77
Noncurrent Deferred & Refundable Income Taxes	16	35	35
Other Noncurrent Operating Assets	1,324	1,331	1,336
Total Liabilities & Shareholders' Equity	4,911	4,800	4,609
Total Liabilities	3,347	3,413	3,446
Total Current Liabilities	830	887	909
Short-Term Debt	18	12	11
Accounts Payable	372	369	371
Accrued Expenses	440	506	527
Total Noncurrent Liabilities	2,517	2,526	2,537
Long-Term Debt	1,091	1,084	1,082
Other Noncurrent Operating Liabilities	1,426	1,442	1,456
Commitments & Contingencies	0.00	0.00	0.00
Redeemable Noncontrolling Interest	-0.19	2.39	3.67
Total Equity & Noncontrolling Interests	1,565	1,384	1,159
Total Preferred & Common Equity	1,175	1,006	740
Preferred Stock	0.00	0.00	-
Total Common Equity	1,175	1,006	740
Common Stock	764	745	498
Retained Earnings	407	252	225
Accumulated Other Comprehensive Income / (Loss)	3.93	9.49	17
Noncontrolling Interest	390	379	419

This table displays calculated financial ratios and metrics derived from Ardent Health Partners' official financial filings.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Growth Metrics	-	-	-
Revenue Growth	10.29%	5.45%	0.00%
EBITDA Growth	73.08%	-0.03%	0.00%
EBIT Growth	139.46%	-1.34%	0.00%
NOPAT Growth	117.88%	-2.53%	0.00%
Net Income Growth	132.37%	-51.40%	0.00%
EPS Growth	267.44%	-71.33%	0.00%
Operating Cash Flow Growth	42.10%	677.96%	0.00%
Free Cash Flow Firm Growth	102.88%	0.00%	0.00%
Invested Capital Growth	12.50%	0.00%	0.00%
Revenue Q/Q Growth	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	0.00%	0.00%	0.00%
EBIT Q/Q Growth	0.00%	0.00%	0.00%
NOPAT Q/Q Growth	0.00%	0.00%	0.00%
Net Income Q/Q Growth	0.00%	0.00%	0.00%
EPS Q/Q Growth	0.00%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	0.00%	0.00%	0.00%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%
Invested Capital Q/Q Growth	0.00%	0.00%	0.00%
Profitability Metrics	-	-	-
Gross Margin	57.51%	55.93%	30.00%
EBITDA Margin	8.63%	5.50%	5.80%
Operating Margin	5.65%	2.77%	3.00%
EBIT Margin	6.09%	2.80%	3.00%
Profit (Net Income) Margin	5.02%	2.38%	5.17%
Tax Burden Percent	82.55%	85.07%	85.20%
Interest Burden Percent	100.00%	100.00%	202.69%
Effective Tax Rate	17.45%	14.93%	14.80%
Return on Invested Capital (ROIC)	14.29%	13.93%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	17.65%	14.30%	0.00%
Return on Net Nonoperating Assets (RNNOA)	8.73%	9.90%	0.00%
Return on Equity (ROE)	23.01%	23.83%	0.00%
Cash Return on Invested Capital (CROIC)	2.52%	-186.07%	0.00%
Operating Return on Assets (OROA)	7.50%	3.20%	0.00%
Return on Assets (ROA)	6.19%	2.73%	0.00%
Return on Common Equity (ROCE)	15.92%	14.77%	0.00%
Return on Equity Simple (ROE_SIMPLE)	26.49%	19.22%	0.00%
Net Operating Profit after Tax (NOPAT)	278	128	131
NOPAT Margin	4.66%	2.36%	2.55%
Net Nonoperating Expense Percent (NNEP)	-3.37%	-0.37%	0.00%
Return On Investment Capital (ROIC_SIMPLE)	10.63%	5.64%	-
Cost of Revenue to Revenue	42.49%	44.07%	70.00%
SG&A Expenses to Revenue	44.02%	44.84%	23.41%
R&D to Revenue	0.00%	0.00%	0.00%
Operating Expenses to Revenue	51.87%	53.16%	27.01%
Earnings before Interest and Taxes (EBIT)	363	152	154
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	515	297	298
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	2.15	0.29	0.00
Price to Tangible Book Value (P/TBV)	12.05	0.00	0.00
Price to Revenue (P/Rev)	0.41	0.04	0.04
Price to Earnings (P/E)	11.59	3.56	6.17
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	8.63%	28.08%	16.20%
Enterprise Value to Invested Capital (EV/IC)	1.63	0.74	0.00
Enterprise Value to Revenue (EV/Rev)	0.56	0.25	0.00
Enterprise Value to EBITDA (EV/EBITDA)	6.54	4.55	0.00
Enterprise Value to EBIT (EV/EBIT)	9.27	8.92	0.00
Enterprise Value to NOPAT (EV/NOPAT)	12.11	10.60	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	10.69	6.10	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	68.72	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	0.72	1.10	0.00
Long-Term Debt to Equity	0.71	1.08	0.00
Financial Leverage	0.49	0.69	0.00
Leverage Ratio	3.72	4.37	0.00
Compound Leverage Factor	3.72	4.37	0.00
Debt to Total Capital	41.84%	52.30%	0.00%
Short-Term Debt to Total Capital	0.35%	0.82%	0.00%
Long-Term Debt to Total Capital	41.48%	51.48%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	14.94%	18.13%	0.00%
Common Equity to Total Capital	43.23%	29.57%	0.00%
Debt to EBITDA	2.13	3.99	0.00
Net Debt to EBITDA	1.05	2.52	0.00
Long-Term Debt to EBITDA	2.11	3.93	0.00
Debt to NOPAT	3.94	9.30	0.00
Net Debt to NOPAT	1.94	5.87	0.00
Long-Term Debt to NOPAT	3.91	9.16	0.00
Altman Z-Score	2.19	1.48	0.00
Noncontrolling Interest Sharing Ratio	30.81%	38.01%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	1.94	1.63	0.00
Quick Ratio	1.37	1.22	0.00
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	49	-1,704	0.00
Operating Cash Flow to CapEx	168.01%	161.34%	-25.39%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00
Efficiency Ratios	-	-	-
Asset Turnover	1.23	1.14	0.00
Accounts Receivable Turnover	7.86	6.98	0.00
Inventory Turnover	22.98	22.60	0.00
Fixed Asset Turnover	7.13	6.67	0.00
Accounts Payable Turnover	5.79	5.02	0.00
Days Sales Outstanding (DSO)	46.45	52.32	0.00
Days Inventory Outstanding (DIO)	15.88	16.15	0.00
Days Payable Outstanding (DPO)	63.06	72.65	0.00
Cash Conversion Cycle (CCC)	-0.72	-4.18	0.00
Capital & Investment Metrics	-	-	-
Invested Capital	2,061	1,832	0.00
Invested Capital Turnover	3.07	5.91	0.00
Increase / (Decrease) in Invested Capital	229	1,832	0.00
Enterprise Value (EV)	3,367	1,353	0.00
Market Capitalization	2,438	192	192
Book Value per Share	$7.93	$5.32	$0.00
Tangible Book Value per Share	$1.42	($1.99)	$0.00
Total Capital	2,617	2,269	0.00
Total Debt	1,095	1,187	0.00
Total Long-Term Debt	1,086	1,168	0.00
Net Debt	538	749	0.00
Capital Expenditures (CapEx)	188	137	151
Debt-free, Cash-free Net Working Capital (DFCFNWC)	340	205	0.00
Debt-free Net Working Capital (DFNWC)	897	643	0.00
Net Working Capital (NWC)	887	624	0.00
Net Nonoperating Expense (NNE)	-22	-1.37	-134
Net Nonoperating Obligations (NNO)	538	749	0.00
Total Depreciation and Amortization (D&A)	152	146	144
Debt-free, Cash-free Net Working Capital to Revenue	5.70%	3.79%	0.00%
Debt-free Net Working Capital to Revenue	15.03%	11.88%	0.00%
Net Working Capital to Revenue	14.87%	11.53%	0.00%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	$1.59	$0.00	$0.00
Adjusted Weighted Average Basic Shares Outstanding	132.44M	0.00	0.00
Adjusted Diluted Earnings per Share	$1.58	$0.00	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	132.74M	0.00	0.00
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	142.75M	0.00	0.00
Normalized Net Operating Profit after Tax (NOPAT)	278	128	131
Normalized NOPAT Margin	4.66%	2.36%	2.55%
Pre Tax Income Margin	6.09%	2.80%	6.07%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00
Payout Ratios	-	-	-
Dividend Payout Ratio	24.31%	49.52%	92.02%
Augmented Payout Ratio	27.49%	69.70%	92.75%

This table displays calculated financial ratios and metrics derived from Ardent Health Partners' official financial filings.

Metric	Q1 2025	Q3 2024	Q2 2024	Q3 2023	Q2 2023
Period end date	3/31/2025	9/30/2024	6/30/2024	9/30/2023	6/30/2023
Growth Metrics	-	-	-	-	-
Revenue Growth	4.04%	5.23%	7.47%	0.00%	0.00%
EBITDA Growth	19.60%	14.88%	17.47%	0.00%	0.00%
EBIT Growth	31.18%	24.14%	23.98%	0.00%	0.00%
NOPAT Growth	-8.29%	13.01%	23.55%	0.00%	0.00%
Net Income Growth	28.60%	18.85%	20.20%	0.00%	0.00%
EPS Growth	38.10%	11.76%	30.77%	0.00%	0.00%
Operating Cash Flow Growth	-68.75%	1.19%	0.00%	0.00%	0.00%
Free Cash Flow Firm Growth	0.00%	0.00%	0.00%	0.00%	0.00%
Invested Capital Growth	0.00%	0.00%	0.00%	0.00%	0.00%
Revenue Q/Q Growth	0.00%	-1.43%	0.00%	0.66%	0.00%
EBITDA Q/Q Growth	0.00%	-20.91%	0.00%	-19.13%	0.00%
EBIT Q/Q Growth	0.00%	-32.13%	0.00%	-32.22%	0.00%
NOPAT Q/Q Growth	0.00%	-35.96%	0.00%	-29.98%	0.00%
Net Income Q/Q Growth	0.00%	-31.30%	0.00%	-30.51%	0.00%
EPS Q/Q Growth	0.00%	-44.12%	0.00%	-34.62%	0.00%
Operating Cash Flow Q/Q Growth	-120.73%	0.00%	0.00%	0.00%	0.00%
Free Cash Flow Firm Q/Q Growth	0.00%	-1.26%	0.00%	0.00%	0.00%
Invested Capital Q/Q Growth	0.00%	-0.06%	0.00%	0.00%	0.00%
Profitability Metrics	-	-	-	-	-
Gross Margin	56.08%	56.19%	57.57%	56.77%	56.29%
EBITDA Margin	7.46%	6.57%	8.18%	6.02%	7.49%
Operating Margin	3.53%	3.74%	5.70%	3.34%	4.92%
EBIT Margin	4.96%	3.94%	5.72%	3.34%	4.95%
Profit (Net Income) Margin	3.94%	3.17%	4.55%	2.81%	4.07%
Tax Burden Percent	79.47%	80.62%	81.48%	84.20%	82.14%
Interest Burden Percent	100.00%	100.00%	97.74%	100.00%	100.00%
Effective Tax Rate	20.53%	19.38%	18.52%	15.80%	17.86%
Return on Invested Capital (ROIC)	15.54%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	21.05%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	8.25%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	23.79%	0.00%	0.00%	0.00%	0.00%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	6.08%	0.00%	0.00%	0.00%	0.00%
Return on Assets (ROA)	4.83%	0.00%	0.00%	0.00%	0.00%
Return on Common Equity (ROCE)	17.87%	0.00%	0.00%	0.00%	0.00%
Return on Equity Simple (ROE_SIMPLE)	26.62%	0.00%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	42	44	68	39	55
NOPAT Margin	2.81%	3.02%	4.64%	2.81%	4.04%
Net Nonoperating Expense Percent (NNEP)	-5.52%	-0.85%	0.35%	0.00%	0.00%
Return On Investment Capital (ROIC_SIMPLE)	1.57%	-	-	-	-
Cost of Revenue to Revenue	43.92%	43.81%	42.43%	43.23%	43.71%
SG&A Expenses to Revenue	44.78%	44.40%	43.96%	45.05%	43.57%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	52.54%	52.44%	51.87%	53.43%	51.37%
Earnings before Interest and Taxes (EBIT)	74	57	84	46	68
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	112	95	120	83	102
Valuation Ratios	-	-	-	-	-
Price to Book Value (P/BV)	1.67	2.61	0.26	0.00	0.00
Price to Tangible Book Value (P/TBV)	8.86	34.10	0.00	0.00	0.00
Price to Revenue (P/Rev)	0.33	0.00	0.00	0.00	0.00
Price to Earnings (P/E)	8.74	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	11.45%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	1.36	1.84	0.71	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.49	0.00	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	5.56	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	7.79	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	10.83	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	9.72	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-
Debt to Equity	0.71	0.79	0.94	0.00	0.00
Long-Term Debt to Equity	0.70	0.78	0.93	0.00	0.00
Financial Leverage	0.39	0.38	0.65	0.00	0.00
Leverage Ratio	3.14	3.46	3.96	0.00	0.00
Compound Leverage Factor	3.14	3.46	3.87	0.00	0.00
Debt to Total Capital	41.47%	44.14%	48.45%	0.00%	0.00%
Short-Term Debt to Total Capital	0.66%	0.49%	0.48%	0.00%	0.00%
Long-Term Debt to Total Capital	40.80%	43.65%	47.97%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	14.57%	15.35%	18.74%	0.00%	0.00%
Common Equity to Total Capital	43.97%	40.51%	32.81%	0.00%	0.00%
Debt to EBITDA	2.08	0.00	0.00	0.00	0.00
Net Debt to EBITDA	1.15	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	2.05	0.00	0.00	0.00	0.00
Debt to NOPAT	4.05	0.00	0.00	0.00	0.00
Net Debt to NOPAT	2.24	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	3.98	0.00	0.00	0.00	0.00
Altman Z-Score	1.97	0.00	0.00	0.00	0.00
Noncontrolling Interest Sharing Ratio	24.89%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-
Current Ratio	2.12	1.91	1.65	0.00	0.00
Quick Ratio	1.53	1.43	1.16	0.00	0.00
Cash Flow Metrics	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-2,136	-1,876	-1,853	0.00	0.00
Operating Cash Flow to CapEx	-108.20%	206.37%	0.00%	354.48%	0.00%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	-976.03	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-
Asset Turnover	1.23	0.00	0.00	0.00	0.00
Accounts Receivable Turnover	7.76	0.00	0.00	0.00	0.00
Inventory Turnover	21.36	0.00	0.00	0.00	0.00
Fixed Asset Turnover	7.03	0.00	0.00	0.00	0.00
Accounts Payable Turnover	6.91	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	47.05	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	17.09	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	52.80	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	11.33	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-
Invested Capital	2,178	1,920	1,921	0.00	0.00
Invested Capital Turnover	5.53	0.00	0.00	0.00	0.00
Increase / (Decrease) in Invested Capital	2,178	1,920	1,921	0.00	0.00
Enterprise Value (EV)	2,965	3,538	1,373	0.00	0.00
Market Capitalization	1,963	2,624	192	192	192
Book Value per Share	$8.23	$7.05	$5.87	$0.00	$0.00
Tangible Book Value per Share	$1.55	$0.54	($1.50)	$0.00	$0.00
Total Capital	2,673	2,483	2,255	0.00	0.00
Total Debt	1,108	1,096	1,093	0.00	0.00
Total Long-Term Debt	1,091	1,084	1,082	0.00	0.00
Net Debt	613	533	758	0.00	0.00
Capital Expenditures (CapEx)	23	43	0.00	25	0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)	454	252	269	0.00	0.00
Debt-free Net Working Capital (DFNWC)	949	816	603	0.00	0.00
Net Working Capital (NWC)	931	803	593	0.00	0.00
Net Nonoperating Expense (NNE)	-17	-2.26	1.34	0.00	-0.43
Net Nonoperating Obligations (NNO)	613	533	758	0.00	0.00
Total Depreciation and Amortization (D&A)	37	38	36	37	35
Debt-free, Cash-free Net Working Capital to Revenue	7.53%	0.00%	0.00%	0.00%	0.00%
Debt-free Net Working Capital to Revenue	15.75%	0.00%	0.00%	0.00%	0.00%
Net Working Capital to Revenue	15.46%	0.00%	0.00%	0.00%	0.00%
Earnings Adjustments	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.30	$0.19	$0.34	$0.00	$0.00
Adjusted Weighted Average Basic Shares Outstanding	140.06M	137.11M	126.12M	0.00	0.00
Adjusted Diluted Earnings per Share	$0.29	$0.19	$0.34	$0.00	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	140.70M	137.54M	126.12M	0.00	0.00
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	143.04M	142.73M	142.76M	0.00	0.00
Normalized Net Operating Profit after Tax (NOPAT)	42	44	68	39	55
Normalized NOPAT Margin	2.81%	3.02%	4.64%	2.81%	4.04%
Pre Tax Income Margin	4.96%	3.94%	5.59%	3.34%	4.95%
Debt Service Ratios	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	44.30	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	35.99	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-
Dividend Payout Ratio	24.88%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	24.88%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Ardent Health Partners' Financials

When does Ardent Health Partners's fiscal year end?

According to the most recent income statement we have on file, Ardent Health Partners' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Ardent Health Partners' net income changed over the last 2 years?

Ardent Health Partners' net income appears to be on an upward trend, with a most recent value of $299.71 million in 2024, rising from $265.37 million in 2022. The previous period was $128.98 million in 2023. See Ardent Health Partners' forecast for analyst expectations on what’s next for the company.

What is Ardent Health Partners's operating income?

Ardent Health Partners's total operating income in 2024 was $336.80 million, based on the following breakdown:

Total Gross Profit: $3.43 billion
Total Operating Expenses: $3.09 billion

How has Ardent Health Partners revenue changed over the last 2 years?

Over the last 2 years, Ardent Health Partners' total revenue changed from $5.13 billion in 2022 to $5.97 billion in 2024, a change of 16.3%.

How much debt does Ardent Health Partners have?

Ardent Health Partners' total liabilities were at $3.43 billion at the end of 2024, a 5.9% decrease from 2023, and a 5.9% decrease since 2023.

How much cash does Ardent Health Partners have?

In the past 1 years, Ardent Health Partners' cash and equivalents has ranged from $437.58 million in 2023 to $556.79 million in 2024, and is currently $556.79 million as of their latest financial filing in 2024.

How has Ardent Health Partners' book value per share changed over the last 2 years?

Over the last 2 years, Ardent Health Partners' book value per share changed from 0.00 in 2022 to 7.93 in 2024, a change of 792.7%.

Related Companies

This page (NYSE:ARDT) was last updated on 5/25/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ardent Health Partners (ARDT) Financials

Frequently Asked Questions About Ardent Health Partners' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ardent Health Partners (ARDT) Financials

Annual Income Statements for Ardent Health Partners

Quarterly Income Statements for Ardent Health Partners

Annual Cash Flow Statements for Ardent Health Partners

Quarterly Cash Flow Statements for Ardent Health Partners

Annual Balance Sheets for Ardent Health Partners

Quarterly Balance Sheets for Ardent Health Partners

Annual Metrics And Ratios for Ardent Health Partners

Quarterly Metrics And Ratios for Ardent Health Partners

Frequently Asked Questions About Ardent Health Partners' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools